Mergers & Acquisitions Mergers & Acquisitions

Illumina-Grail merger was wrongly reviewed by EU regulator, top court rules

Gene-sequencing specialist Illumina has won its fight with the European Commission over its purchase of cancer-testing company Grail, with the EU’s top court concluding today that the regulator did not have the power to review the deal.
In a landmark ruling (see here), the Court of Justice said: "The commission

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Natalie McNelis

Senior Correspondent


Natalie McNelis covers mergers for MLex in Brussels. Before joining MLex in 2017, she spent 20 years as an international trade and competition lawyer in law firms including Stibbe and WilmerHale. Natalie has a BA in English from Mount Holyoke College, a JD from Harvard Law School and an LLM in EU law from KU Leuven. She is admitted to the bar in New York.

Lewis Crofts

Editor-In-Chief


Lewis leads MLex's editorial strategy, content direction, quality and development. He has a reputation for breaking stories and providing analysis on complex legal disputes before regulators and courts around the globe. He has also developed MLex's unrivalled coverage of competition policy, litigation, regulation, Brexit and international investigations.

Discover MLex

Stay on top of global regulatory developments

Latest News